| Literature DB >> 32210935 |
Hua Zou1, Xiaojiong Jia1, Hang Liu1, Shuang Li1, Xianan Wu1, Shifeng Huang1.
Abstract
The newly emerging NDM-5 confers increased antibiotic resistance and attracts extensive global attention, but the prevalence, dissemination mechanism, and clinical significance of NDM-5 among clinical Escherichia coli (E. coli) infections have not been thoroughly characterized to date. In the present study, 109 unique carbapenem-resistant E. coli (CR-EC) isolates were collected in Southwest China, from 2013 to 2017, among which 41 (37.61%) CR-EC isolates were identified as NDM-5-producers, with most isolates carrying the IncF-type plasmids. Molecular epidemiological studies revealed ST167 being the most common sequence type (ST). Moreover, we described the first report of a clinical CR-EC isolate co-harboring bla KPC- 2 and bla NDM- 5, which showed a higher level of resistance to carbapenems. In addition, bla NDM- 5 plasmid transformation and conjugation indicated that bla NDM- 5 itself did confer resistance to carbapenems. Complete sequencing of the bla NDM- 5-harboring IncF plasmid revealed highly conserved regions (ble MBL-trpF-tat) and some transposons around bla NDM- 5. Our findings revealed a new potential threat of NDM-5-postive CR-EC in mainland China and emphasized an urgent need to control their further spread.Entities:
Keywords: Escherichia coli; NDM-5; carbapenem resistant; conjugation; transformation
Year: 2020 PMID: 32210935 PMCID: PMC7069339 DOI: 10.3389/fmicb.2020.00334
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Antimicrobial susceptibility of CR-EC isolates with or without carbapenemases.
| Antimicrobial agents | Total ( | Carbapenemase positive ( | Carbapenemase negative ( | |||||||
| R (%) | R | MIC50 | MIC90 | Range | R | MIC50 | MIC90 | Range | ||
| Ertapenem | 106 (97.3) | 50 (100.0) | 32 | 256 | 2–512 | 56 (94.9) | 4 | 64 | 1–512 | < 0.001 |
| Imipenem | 63 (57.8) | 50 (100.0) | 32 | 128 | 4–512 | 13 (22.0) | 1 | 8 | 0.25–32 | < 0.001 |
| Meropenem | 61 (55.9) | 48 (96.0) | 8 | 54 | 0.25–256 | 13 (22.0) | 1 | 8 | 0.25–8 | < 0.001 |
| Ceftriaxone | 109 (100.0) | 50 (100.0) | 128 | 512 | 64–512 | 59 (100.0) | 64 | 128 | 16–512 | – |
| Ceftazidime | 102 (93.6) | 50 (100.0) | 128 | 512 | 64–512 | 52 (88.2) | 64 | 128 | 1–256 | < 0.001 |
| Cefepime | 101 (92.7) | 49 (98.0) | 128 | 512 | 8–512 | 52 (88.1) | 64 | 128 | 1–256 | < 0.001 |
| Aztreonam | 97 (88.9) | 48 (96.0) | 128 | 512 | 8–512 | 49 (83.0) | 64 | 256 | 2–256 | < 0.001 |
| Ciprofloxacin | 85 (77.9) | 41 (82.0) | 16 | 32 | 0.25–32 | 44 (74.6) | 4 | 8 | 0.25–16 | < 0.001 |
| Levofloxacin | 76 (69.7) | 37 (74.0) | 16 | 64 | 0.25–64 | 39 (66.1) | 8 | 8 | 0.25–32 | < 0.001 |
| Gentamycin | 70 (64.2) | 34 (68.0) | 32 | 128 | 1–512 | 36 (61.0) | 16 | 16 | 1–32 | 0.02 |
| Tobramycin | 51 (46.8) | 24 (48.0) | 8 | 128 | 1–512 | 27 (45.8) | 8 | 16 | 1–32 | 0.735 |
| Colistin | 22 (20.2) | 12 (24.0) | 1 | 4 | 1–8 | 10 (16.9) | 1 | 8 | 1–8 | 0.988 |
| Tigecycline | 0 (0.00) | 0 (0.00) | 1 | 4 | 0.25–4 | 0 (0.0) | 0.25 | 1 | 0.25–2 | – |
Presence of antibiotic resistance genes in clinical carbapenemase-positive and carbapenemase-negative CR-EC isolates.
| Carbapenem resistance mechanisms | Total (109) | Carbapenemase positive (50) | Carbapenemase negative (59) | |
| Carbapenemase type(s) | 50(45.9%) | |||
| NDM- positive | NDM-1 | 8(7.3%) | 8(16.0%) | NA |
| NDM-5 | 41(37.6%) | 41(82.0%) | ||
| NDM-9 | 1(0.9%) | 1(2.0%) | ||
| KPC- positive | KPC-2 | 1(0.9%) | 1(2.0%) | NA |
| NDM-5, KPC-2 | 1(0.9%) | 1(2.0%) | NA | |
| ESBL type(s) | 83(76.2%) | |||
| CTXM- positive | CTXM-1 | 46(42.2%) | 24(48.0%) | 22 (37.3%) |
| CTXM-9 | 25(22.9%) | 16(32.0%) | 9 (15.3%) | |
| CTXM-15 | 23(21.1%) | 16(32.0%) | 7 (11.9%) | |
| TEM- positive | TEM-1 | 35(32.1%) | 29(58.0%) | 6 (10.2%) |
| OXA-1-positive | OXA-1 | 23(21.1%) | 8(16.0%) | 15 (25.4%) |
| OMPs loss | 32(29.4%) | |||
| OMPs | OmpC | 27(24.8%) | 12(24.0%) | 15 (25.4%) |
| OmpF | 21(19.3%) | 11(22.0%) | 10 (16.9%) | |
| OmpC, OmpF | 16(14.7%) | 4(8.0%) | 12 (20.3%) | |
| Carbapenemase, ESBL type | 50(45.9%) | 50(100.0%) | NA | |
| Carbapenemase, ESBL type, OMPs loss | 12(11.0%) | 12(24.0%) | NA | |
| Carbapenemase, OMPs loss | 12(11.0%) | 12(24.0%) | NA | |
| ESBL type, OMPs loss | 27(24.8%) | 12(24.0%) | 15 (25.4%) | |
Profiles of plasmids and corresponding average carbapenem MICs in 50 blaNDM-positive E. coli clinical isolates.
| Characteristics | NDM-5 | NDM-1 | NDM-9 | |
| Average MICs (μg/ml) | ETP | 84.79 | 31.75 | 8 |
| IPM | 55.10 | 31 | 8 | |
| MEM | 27.67 | 8.13 | 4 | |
| MLST | ST167 (10) | ST167 (1) | ST167 (1) | |
| ST410 (5) | ST361 (1) | |||
| ST354 (3) | ST4538 (1) | |||
| ST973 (2) | ST453 (1) | |||
| ST746 (2) | Unknown ST (4) | |||
| Unknown ST (8) Other types (11) | ||||
| Replicon type | IncF (26) | IncF (6) | IncF (1) | |
| IncX (9) | IncX (2) | |||
| IncA/C (1) | ||||
| IncH (3) UnknownType (2) | ||||
FIGURE 1Dendrogram analysis and molecular epidemiology of NDM-5 positive Escherichia coli isolates. The dendrogram is based on the similarity of PFGE patterns from 41 blaNDM–5 positive clinical E. coli isolates. The right columns illustrate results of source, date, PFGE, MLST, ESBLs, and plasmid types.
FIGURE 2Schematic map of plasmid pNDM-5-1001 and comparative analysis of plasmid pNDM-5-1001 with other three blaNDM–5-carrying plasmids and pNDM-BJ01. Reference sequences: pNDM-BJ01 from an Acinetobacter lwoffii strain (GenBank accession No. JQ001791), pNDM-5-IT from an E. coli strain (GenBank accession No. MG649062.1), pGUE_NDM from an E. coli strain (GenBank accession number JQ364967.1), and pNDM5-020007 from an E. coli strain (GenBank accession number CP025626.1).
FIGURE 3Comparison of the genetic elements surrounding the blaNDM–5 gene identified in this study with the other similar sequences. Reference sequences: pNDM-BJ01 (GenBank accession No. JQ001791) from an A. lwoffii strain, p744T-NDM5 (GenBank accession No. MF547511.1) from an E. coli strain, and pNDM-5-IT (GenBank accession No. MG649062.1) from an E. coli strain.